Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets, 1 mg and 2 mg.".
Alembic Pharmaceuticals Limited Press Release Jul 28 2026
Filed with NSE · · 2 pages · English
Release
Alembic Pharmaceuticals Limited on 6ix
Earlier from Alembic Pharmaceuticals
- Alembic Pharmaceuticals Limited Press Release Jul 18 2026
- Alembic Pharmaceuticals Limited Press Release Jun 26 2026
- Alembic Pharmaceuticals Limited Press Release Jun 19 2026
- Alembic Pharmaceuticals Limited Press Release Jun 12 2026
- Alembic Pharmaceuticals Limited Press Release Jun 11 2026
Later from Alembic Pharmaceuticals
- Alembic Pharmaceuticals Limited Press Release Aug 04 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg.
- Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2026".
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals